Biotechnology company ViAqua Therapeutics announced that its recently-completed 4.3 million (EUR 3.5 million) funding round will be used to support the commercialization of its first product dedicated to improving shrimp health …

Photo courtesy of ViAqua Therapeutics

Visit source site

LEAVE A REPLY

Please enter your comment!
Please enter your name here